New Huntington’s treatment prevents protein aggregation
New Huntington’s treatment prevents protein aggregation
November 1, 2024
The Gianneschi Group, in collaboration with researchers from Case Western Reserve University, has developed the first polymer-based therapy for Huntington’s disease—an incurable, debilitating illness that causes nerve cell breakdown in the brain. This innovative treatment uses peptide-brush polymers that act as a protective shield, preventing harmful protein binding. In studies with mice, the therapy successfully preserved neurons and reversed symptoms. Additionally, the treated mice showed no significant side effects, confirming that the therapy is both nontoxic and well tolerated.
